Obe-cel as 1L consolidation therapy for LBCL patients in CMR and MRD+
Research type
Research Study
Full title
A Phase 3, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Obecabtagene Autoleucel Consolidation Versus Observation at End of First-line Treatment in MRD Positive Patients with Large B Cell Lymphoma
IRAS ID
1012369
Contact name
Nirav Patel
Contact email
Sponsor organisation
Autolus Limited UK
Eudract number
2024-519689-39
Research summary
Summary of Research
Researchers are looking for a way to treat a blood cancer called large B cell lymphoma (LBCL). LBCL happens when a type of white blood cell, called a B cell, grows too much and forms tumours (lumps). In healthy people, B cells grow normally and help the immune system to keep you well.
Standard (usual) treatments given to people with LBCL will kill B cells and scans may show that the cancer is gone. For some people, a small amount of cancer cells may remain in the body and may cause cancer to come back. This is called measurable residual disease (MRD).
In this trial, researchers are testing a new treatment called obe-cel. Obe-cel is made in the laboratory using another type of white blood cell, called T cells. These T cells are collected from the same person who will be receiving obe cel (a method called leukapheresis).
This trial will test obe-cel treatment in participants with LBCL whose scans show no signs of cancer after their usual LBCL treatment and who also have positive MRD status, which is found by a blood test (also known as a liquid biopsy). In this trial, we will use the investigational diagnostic test, clonoSEQ plasma MRD assay (Adaptive Biotechnologies). The goal of obe-cel treatment is to kill B cells and any remaining cancer cells to lower the chances of cancer coming back and to keep the participant cancer-free for a longer time.This is an open-label, randomised trial. Participants who are a good fit for the trial will be randomised to either the “obe-cel consolidation” group (where they will receive obe-cel), or to the “observation” group (where they will not receive obe-cel and will be monitored in the same way as usual). In the first 28 days after obe-cel treatment, the participant’s temperature will be checked every day. All participants will have regular checkups, blood tests, and scans for up to 2 years. After 2 years, participants receive usual medical care and blood tests (including MRD) until the trial ends ).
Summary of Results
This trial did not initiate and therefore it is not available for recruitment. No participants were enrolled on study.REC name
London - West London & GTAC Research Ethics Committee
REC reference
25/LO/0689
Date of REC Opinion
30 Oct 2025
REC opinion
Further Information Favourable Opinion